<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Mol Hepatol</journal-id><journal-id journal-id-type="iso-abbrev">Clin Mol Hepatol</journal-id><journal-id journal-id-type="pmc-domain-id">1864</journal-id><journal-id journal-id-type="pmc-domain">cmh</journal-id><journal-id journal-id-type="publisher-id">CMH</journal-id><journal-title-group><journal-title>Clinical and Molecular Hepatology</journal-title></journal-title-group><issn pub-type="ppub">2287-2728</issn><issn pub-type="epub">2287-285X</issn><publisher><publisher-name>Korean Association for the Study of the Liver</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10029953</article-id><article-id pub-id-type="pmcid-ver">PMC10029953.1</article-id><article-id pub-id-type="pmcaid">10029953</article-id><article-id pub-id-type="pmcaiid">10029953</article-id><article-id pub-id-type="pmid">36537018</article-id><article-id pub-id-type="doi">10.3350/cmh.2022.0437</article-id><article-id pub-id-type="publisher-id">cmh-2022-0437</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0110-0965</contrib-id><name name-style="western"><surname>An</surname><given-names initials="J">Jihyun</given-names></name><xref rid="c1-cmh-2022-0437" ref-type="corresp"/><xref rid="af1-cmh-2022-0437" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sohn</surname><given-names initials="JH">Joo Hyun</given-names></name><xref rid="af1-cmh-2022-0437" ref-type="aff"/></contrib><aff id="af1-cmh-2022-0437">
Department of Gastroenterology and Hepatology, Hanyang University College of Medicine, Guri, <country>Korea</country></aff></contrib-group><author-notes><corresp id="c1-cmh-2022-0437">Corresponding author : Jihyun An Department of Gastroenterology and Hepatology, Hanyang University College of Medicine, 153 Gyeongchun-ro, Guri 11923, Korea Tel: +82-31-560-2234, Fax: +82-31-560-2539, E-mail: <email>starlit1@naver.com</email></corresp><fn id="fn1-cmh-2022-0437"><p>Editor: Won Kim, Seoul Metropolitan Boramae Hospital, Korea</p></fn></author-notes><pub-date pub-type="ppub"><month>2</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>20</day><month>12</month><year>2022</year></pub-date><volume>29</volume><issue>Suppl</issue><issue-id pub-id-type="pmc-issue-id">431765</issue-id><fpage>S268</fpage><lpage>S275</lpage><history><date date-type="received"><day>5</day><month>12</month><year>2022</year></date><date date-type="rev-recd"><day>15</day><month>12</month><year>2022</year></date><date date-type="accepted"><day>15</day><month>12</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>02</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>22</day><month>03</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-03-22 05:11:14.120"><day>22</day><month>03</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2023 by The Korean Association for the Study of the Liver</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/3.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="cmh-2022-0437.pdf"/><abstract><p>Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a progressive form of NAFLD, is characterized by hepatocellular injury, inflammation, and fibrosis. Patients with NASH or severe fibrosis should be treated according to international NAFLD guidelines. Currently, regulatory agencies have not approved any pharmaceutical treatment for NAFLD. Vitamin E and pioglitazone are efficacious for NASH resolution; however, their benefits must be weighed against the reported risks. In a phase 2 trial, a glucagon-like peptide-1 agonist commonly used for diabetes and obesity was found to improve liver histology in patients with NASH. Furthermore, therapeutic agents targeting NASH pathogenesis, including bile acid signaling, insulin resistance, and lipid metabolism, are in various phases of clinical development. In this article, we review the benefits and drawbacks of current pharmacotherapy and the efficacy of upcoming treatments for NASH.</p></abstract><kwd-group><kwd>Nonalcoholic fatty liver disease</kwd><kwd>Nonalcoholic steatohepatitis</kwd><kwd>Treatment</kwd><kwd>Drugs</kwd><kwd>Clinical trials</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Nonalcoholic fatty liver disease (NAFLD) affects approximately one-quarter of the adult population worldwide, making it the most common liver disease [<xref rid="b1-cmh-2022-0437" ref-type="bibr">1</xref>]. Nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, is characterized by hepatic triglyceride accumulation, hepatocyte injury, and lobular inflammation [<xref rid="b2-cmh-2022-0437" ref-type="bibr">2</xref>]. NASH is associated with accelerated fibrosis progression to cirrhosis and increased morbidity and mortality from liver disease [<xref rid="b3-cmh-2022-0437" ref-type="bibr">3</xref>]. More than 20% of patients with NASH will develop cirrhosis during their lifespan [<xref rid="b4-cmh-2022-0437" ref-type="bibr">4</xref>]. NASH is the leading indication for liver transplant in the United States [<xref rid="b5-cmh-2022-0437" ref-type="bibr">5</xref>], and it is expected to become the most common cause of hepatocellular carcinoma in developed countries [<xref rid="b6-cmh-2022-0437" ref-type="bibr">6</xref>].</p><p>Patients with NAFLD should be encouraged to lose weight by following a hypocaloric diet and engaging in physical activity [<xref rid="b2-cmh-2022-0437" ref-type="bibr">2</xref>,<xref rid="b7-cmh-2022-0437" ref-type="bibr">7</xref>]. In patients with NASH who are overweight or obese, more than 10% of weight loss due to lifestyle modification is associated with NASH resolution and fibrosis regression [<xref rid="b8-cmh-2022-0437" ref-type="bibr">8</xref>,<xref rid="b9-cmh-2022-0437" ref-type="bibr">9</xref>]. Weight loss also leads to a reduction of liver fat content in non-obese patients with NAFLD [<xref rid="b10-cmh-2022-0437" ref-type="bibr">10</xref>]. However, only a small percentage of patients achieve substantial weight loss, and long-term lifestyle changes are difficult to implement [<xref rid="b8-cmh-2022-0437" ref-type="bibr">8</xref>,<xref rid="b11-cmh-2022-0437" ref-type="bibr">11</xref>]. Therefore, patients with NASH require a practical therapeutic approach.</p><p>Currently, there are no licensed drugs specifically approved for the treatment of NASH. In clinical practice, vitamin E and pioglitazone are efficacious for biopsy-proven NASH [<xref rid="b12-cmh-2022-0437" ref-type="bibr">12</xref>]. Furthermore, glucagon-like peptide 1 (GLP-1) agonists, which are commonly prescribed medications for diabetes and obesity, have the potential to ameliorate NASH [<xref rid="b13-cmh-2022-0437" ref-type="bibr">13</xref>]. The field of NASH treatment is rapidly evolving owing to the rising disease incidence and scarcity of current treatment options. Because the underlying mechanism of NASH is complex, NASH treatments are being developed for a wide range of targets, including oxidative stress, insulin resistance, apoptosis, bile acids, lipid metabolism, and hepatic inflammation and fibrosis. In this article, we review and summarize the efficacy and safety of current treatment options, based primarily on representative data from randomized controlled trials (RCTs), as well as emerging therapies that may enter clinical practice in the future.</p></sec><sec><title>CURRENT PHARMACOLOGIC THERAPIES</title><sec><title>Vitamin E (alpha-tocopherol)</title><p>The imbalance between the reactive oxygen species&#8217; production and scavenging capacity causes oxidative stress [<xref rid="b14-cmh-2022-0437" ref-type="bibr">14</xref>]. Excess hepatic lipid causes reactive oxygen species over-production, accelerating the transition from NAFLD to NASH [<xref rid="b14-cmh-2022-0437" ref-type="bibr">14</xref>]. Vitamin E shows antioxidant properties by increasing specific enzymes and anti-fibrotic actions by regulating the inflammatory response [<xref rid="b15-cmh-2022-0437" ref-type="bibr">15</xref>]. In phase 3 PIVENS trial, patients with NASH without diabetes who received high dose vitamin E (800 IU/day; n=84) for 96 weeks showed a more statistically significant histological improvement, defined as &#8805;2 point reduction in the NAFLD activity score, than the placebo group (n=83) (43% vs. 19%) [<xref rid="b12-cmh-2022-0437" ref-type="bibr">12</xref>]. The proportion of NASH resolution in the vitamin E group was also higher (36% vs. 21%). Recent prospective trials involving patients with NASH and diabetes, found that a combination treatment of vitamin E (800 IU/day) and pioglitazone is more efficacious than a placebo in terms of NASH resolution and steatosis improvement [<xref rid="b16-cmh-2022-0437" ref-type="bibr">16</xref>]. No prospective randomized studies have reported improved liver fibrosis and reduced liver-related death [<xref rid="b16-cmh-2022-0437" ref-type="bibr">16</xref>]. The international NAFLD guidelines suggest vitamin E supplementation for patients with NASH without diabetes (<xref rid="t1-cmh-2022-0437" ref-type="table">Table 1</xref>) [<xref rid="b2-cmh-2022-0437" ref-type="bibr">2</xref>,<xref rid="b7-cmh-2022-0437" ref-type="bibr">7</xref>,<xref rid="b17-cmh-2022-0437" ref-type="bibr">17</xref>]. Unfortunately, although controversial, long-term administration of vitamin E is likely to raise the incidence of prostate cancer and hemorrhagic stroke [<xref rid="b18-cmh-2022-0437" ref-type="bibr">18</xref>].</p></sec><sec><title>Pioglitazone</title><p>Pioglitazone, a peroxisome proliferator-activated receptor (PPAR)-&#947; agonist, reduces insulin resistance in the adipose tissue, muscle, and liver. Several prospective trials reported that patients with or without diabetes who received pioglitazone (30 or 45 mg/day) showed more histological improvement in NASH than those who received placebo [<xref rid="b12-cmh-2022-0437" ref-type="bibr">12</xref>,<xref rid="b19-cmh-2022-0437" ref-type="bibr">19</xref>,<xref rid="b20-cmh-2022-0437" ref-type="bibr">20</xref>]. Cusi et al. [<xref rid="b21-cmh-2022-0437" ref-type="bibr">21</xref>] conducted a single-center study in which patients with prediabetes/diabetes and histologically confirmed NASH were randomly administered either pioglitazone (45 mg/day; n=50) or placebo (n=51). Pioglitazone treatment reduced NAFLD activity score by at least 2 points (58% vs. 17%) and resolved NASH (51% vs. 19%). A meta-analysis of eight RCTs found pioglitazone is efficacious for NASH resolution (odds ratio [OR] 3.22), improvement of advanced fibrosis (OR 3.15), and reversal of fibrosis (OR 1.66) [<xref rid="b22-cmh-2022-0437" ref-type="bibr">22</xref>]. Thus, regardless of the diabetes status, pioglitazone is indicated for biopsy-proven patients with NASH (<xref rid="t1-cmh-2022-0437" ref-type="table">Table 1</xref>) [<xref rid="b2-cmh-2022-0437" ref-type="bibr">2</xref>,<xref rid="b7-cmh-2022-0437" ref-type="bibr">7</xref>,<xref rid="b17-cmh-2022-0437" ref-type="bibr">17</xref>]. It is important to note that weight gain, fluid retention, and increased risk of fracture and bladder cancer are side effects of pioglitazone.</p></sec><sec><title>GLP-1 agonists</title><p>GLP-1 agonists affect glucose regulation by enhancing glucose-dependent insulin release, suppressing postprandial glucagon levels, and slowing gastric emptying. GLP-1 agonist is the mainstay treatment of obesity and diabetes because of their significant therapeutic benefits in weight loss, glycemic control, and improvements in the cardiometabolic system [<xref rid="b23-cmh-2022-0437" ref-type="bibr">23</xref>]. Although the underlying mechanisms of GLP-1 agonists on NASH have not been fully explained, considerable weight loss induced by GLP-1 agonists may lead to subsequent disease improvement. A phase 2 RCT with 320 biopsy-confirmed patients with NASH found that the semaglutide group (0.4 mg once daily for 72 weeks) had a higher proportion of disease resolution than the placebo group (59% vs. 17%) [<xref rid="b24-cmh-2022-0437" ref-type="bibr">24</xref>]. Even though the treatment group had a lower rate of liver fibrosis progression (4.9% vs. 18.8%), there were no significant differences in the proportion of patients whose fibrosis stage improved. The American Association of Clinical Endocrinology guidelines recommend the use of GLP-1 agonist in patients with histology-proven NASH and diabetes [<xref rid="b17-cmh-2022-0437" ref-type="bibr">17</xref>]. A phase 3 ESSENCE trial involving 1,200 patients with NASH and F2-F3 fibrosis is currently investigating the efficacy of semaglutide at a dose of 2.4 mg once-weekly for NASH resolution and fibrosis improvement (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04822181">NCT04822181</ext-link>; <xref rid="t2-cmh-2022-0437" ref-type="table">Table 2</xref>). The most common side effects among patients that receive GLP-1 agonist are gastrointestinal symptoms, such as nausea, vomiting, and diarrhea. GLP-1 agonists may increase the risk of acute pancreatitis, gallbladder disease, and biliary disease. Although GLP-1 agonists are currently used as subcutaneous injections in clinical protocols, oral formulations with improved tolerability are being developed.</p><p>Recently, advances have been made in developing glucagon-containing co-agonists to enhance the efficacy of GLP-1 agonists. A glucagon-stimulated increase in energy expenditure augments the effect of GLP-1-induced weight loss [<xref rid="b25-cmh-2022-0437" ref-type="bibr">25</xref>]. Cotadutide is a dual-receptor agonist with balanced GLP-1 and glucagon action. In phase 2 PROXYMO trial, 74 obese patients with biopsy-proven NASH and F1-F3 fibrosis were randomized to receive once-daily subcutaneous injections of cotadutide (300 &#956;g or 600 &#956;g) or placebo [<xref rid="b26-cmh-2022-0437" ref-type="bibr">26</xref>]. Cotadutide was associated with dose-dependent reductions in hepatic fat compared to the placebo. In the ongoing phase 3 PROXYMOADV trial, cotadutide is expected to show efficacy in treating NASH (<xref rid="t2-cmh-2022-0437" ref-type="table">Table 2</xref>).</p></sec></sec><sec><title>FUTURE PHARMACOLOGIC THERAPIES</title><sec><title>Obeticholic acid</title><p>The farnesoid X receptor is a nuclear receptor activated by bile acids that is abundant in the liver and intestines. It regulates bile synthesis, conjugation, and transport [<xref rid="b27-cmh-2022-0437" ref-type="bibr">27</xref>,<xref rid="b28-cmh-2022-0437" ref-type="bibr">28</xref>], and plays a role in lipid and glucose metabolism [<xref rid="b28-cmh-2022-0437" ref-type="bibr">28</xref>]. The farnesoid X receptor activation can help reduce hepatic inflammation and fibrosis [<xref rid="b29-cmh-2022-0437" ref-type="bibr">29</xref>,<xref rid="b30-cmh-2022-0437" ref-type="bibr">30</xref>].</p><p>Obeticholic acid is a potent and selective farnesoid X receptor agonist. In the interim analysis of phase 3 REGENERATE trial, 931 biopsy-proven patients with NASH and fibrosis stages F2-F3 were randomly assigned to receive obeticholic acid 25 mg daily (n=308), obeticholic acid 10 mg daily (n=312), or placebo (n=311) (<xref rid="t2-cmh-2022-0437" ref-type="table">Table 2</xref>) [<xref rid="b31-cmh-2022-0437" ref-type="bibr">31</xref>]. At 18 months, the obeticholic acid group improved liver fibrosis by at least one stage with no worsening of NASH in a dose-dependent manner (23% vs. 18% vs. 12%, respectively), with no difference in the proportion of NASH resolution (12% vs. 11% vs. 8%, respectively). Indeed, in NASH phase 3 trials, obeticholic acid was the first agent to show a significant improvement in fibrosis. Mild to moderate pruritus was the most common adverse event, affecting up to 51% of patients treated with obeticholic acid 25 mg. Furthermore, nearly 17% of the obeticholic acid group experienced an early increase in low-density lipoprotein cholesterol, which returned to baseline levels at the end of the study. In contrast, in the recent REVERSE trials of 919 randomized patients with compensated NASH cirrhosis, obeticholic acid did not improve fibrosis (11.1% vs. 11.9% vs. 9.9% in obeticholic acid 10 mg vs. obeticholic acid 10 mg titrated to 25 mg vs. placebo, respectively) [<xref rid="b32-cmh-2022-0437" ref-type="bibr">32</xref>]. The US Food and Drug Administration has not yet approved obeticholic acid as a NASH treatment due to its uncertain long-term benefit and safety risks.</p></sec><sec><title>pan-PPAR agonist</title><p>PPARs are a nuclear receptor family with three isotypes that regulate glucose and lipid metabolism, inflammatory cell activation, and fibrotic processes [<xref rid="b33-cmh-2022-0437" ref-type="bibr">33</xref>]. Three PPAR isotypes have been identified: PPAR-&#945;, PPAR-&#946;/&#948;, and PPAR-&#947;. PPAR-&#945; is an essential regulator of fatty acid oxidation that suppresses inflammation by reducing reactive oxygen species formation. PPAR-&#946;/&#948; stimulates hepatic glucose utilization and de novo lipogenesis. PPAR-&#947; regulates adipocyte differentiation and insulin sensitization.</p><p>Lanifibranor (IVA337), a pan-PPAR agonist, demonstrated higher efficacy in terms of improvement of insulin sensitivity, macrophage activation, and reduction of liver fibrosis than single or dual PPAR agonists [<xref rid="b34-cmh-2022-0437" ref-type="bibr">34</xref>,<xref rid="b35-cmh-2022-0437" ref-type="bibr">35</xref>]. In 2021, the results of phase 2b trials comparing lanifibranor 1,200 mg (n=83), lanifibranor 800 mg (n=83), or placebo (n=81) for 24 weeks in patients with biopsy-proven NASH were published [<xref rid="b36-cmh-2022-0437" ref-type="bibr">36</xref>]. The proportion of patients who met the primary endpoint, a decrease of at least 2 points in the SAF-activity score (the activity component of the Steatosis, Activity, Fibrosis [SAF] scoring system that includes hepatocytes ballooning and inflammation), was higher among those who received lanifibranor 1,200 mg than the placebo group (55% vs. 33%). The outcomes favored lanifibranor 1,200 mg over placebo for improvement in the fibrosis stage of at least one without worsening of NASH (48% vs. 29%). Fewer than 10% of patients in the lanifibranor group reported diarrhea, weight gain, and peripheral edema as common adverse effects. An ongoing phase 3 study of lanifibranor for NASH and F2-F3 fibrosis (NATiV3) is also expected to reveal similar results (<xref rid="t2-cmh-2022-0437" ref-type="table">Table 2</xref>).</p><p>In contrast, a phase 3 RCT of the dual PPAR&#945;&#8211;PPAR&#948; agonist elafibranor (RESOLVE- IT) was halted because it failed to meet the predefined primary surrogate efficacy endpoint, NASH resolution without fibrosis worsening the interim analysis [<xref rid="b37-cmh-2022-0437" ref-type="bibr">37</xref>].</p></sec><sec><title>Thyroid hormone receptor &#946;-agonist</title><p>The thyroid hormone regulates glucose and lipid metabolism, in addition to fatty acids oxidation [<xref rid="b38-cmh-2022-0437" ref-type="bibr">38</xref>,<xref rid="b39-cmh-2022-0437" ref-type="bibr">39</xref>]. A selective thyroid hormone receptor beta (THR-&#946;) agonist has been developed to improve liver-specific action while minimizing negative effects on the cardiac and skeletal systems, which are predominantly mediated by THR alpha. Resmetirom, an oral THR-&#946; agonist, was studied in a phase 2 RCT involving 125 overweight or obese adults with biopsy-confirmed NASH and stages 1&#8211;3 fibrosis [<xref rid="b40-cmh-2022-0437" ref-type="bibr">40</xref>]. Resmetirom treatment for 36 weeks resulted in a significant reduction in hepatic fat measured using magnetic resonance imaging (MRI)-proton density fat fraction compared with placebo (-37% vs. -9%). An ongoing phase 3 MAESTRO-NAFLD1 trial is evaluating the impact of resmetirom on liver histology in patients with NASH and stage 2&#8211;3 fibrosis (<xref rid="t2-cmh-2022-0437" ref-type="table">Table 2</xref>). The preliminary results showed that resmetirom was efficacious for hepatic fat assessed using MRI-proton density fat fraction [<xref rid="b41-cmh-2022-0437" ref-type="bibr">41</xref>]. The most prevalent side effects were mild gastrointestinal symptoms, including diarrhea and nausea.</p></sec><sec><title>Selonsertib</title><p>Apoptosis-signal regulating kinase 1 (ASK1) is a member of the mitogen-activated protein kinase (MAPK) family [<xref rid="b42-cmh-2022-0437" ref-type="bibr">42</xref>]. ASK1 is activated in response to oxidative stress and promotes hepatic inflammation and apoptosis, leading to liver fibrogenesis via MAPK downstream signaling. Hence, ASK1 is considered a treatment target for NASH [<xref rid="b43-cmh-2022-0437" ref-type="bibr">43</xref>]. Selonsertib is a first-in-class small-molecule ASK1 inhibitor with antifibrotic and anti-inflammatory effects. Based on the success in phase 2 trials of selonsertib in patients with NASH and F2-F3 fibrosis [<xref rid="b44-cmh-2022-0437" ref-type="bibr">44</xref>], phase 3 RCTs comparing selonsertib 18 mg, selonsertib 6 mg, and placebo were subsequently conducted in patients with NASH and bridging fibrosis (F3, STELLAR-3; n=802) or compensated cirrhosis (F4, STELLAR-4; n=877) (<xref rid="t2-cmh-2022-0437" ref-type="table">Table 2</xref>) [<xref rid="b45-cmh-2022-0437" ref-type="bibr">45</xref>]. The STELLAR-3 trial did not reveal significantly different fibrosis improvement without worsening of NASH between groups (10% vs. 12% vs. 13%, respectively). Moreover, fibrosis improvement was not observed in STELLAR-4 patients with cirrhosis (14% vs. 13% vs. 13%, respectively). In phase 2b ATLAS trial with 392 patients with NASH and F3-F4 fibrosis, selonsertib combination therapy revealed unfavorable outcomes in reversing fibrosis [<xref rid="b46-cmh-2022-0437" ref-type="bibr">46</xref>]. Although selonsertib is no longer being investigated, ASK1 may still be a viable candidate if more effective inhibitors are discovered.</p></sec><sec><title>Other NASH therapies in clinical trials</title><p>The novel medications that have entered phase 3 development stage include armachol (a bile acid and fatty acid analog) [<xref rid="b47-cmh-2022-0437" ref-type="bibr">47</xref>] and cenicriviroc (inhibitor of CC chemokine receptors 2 and 5) (<xref rid="t2-cmh-2022-0437" ref-type="table">Table 2</xref>) [<xref rid="b48-cmh-2022-0437" ref-type="bibr">48</xref>]. Moreover, a large number of additional agents with diverse mechanisms for targeting the pathogenesis of NASH are in phase 2 development [<xref rid="b49-cmh-2022-0437" ref-type="bibr">49</xref>].</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSIONS</title><p>Since the PIVENS study with vitamin E and pioglitazone on NASH resolution was successful in 2010, NASH has been extensively investigated to identify optimal medications. Large-scale RCTs have yielded promising results for farnesoid X receptor, GLP-1, and pan-PPAR agonists in improving hepatic inflammation and fibrosis. However, several obstacles must be overcome before they are approved by the US Food and Drug Administration for NASH treatment: 1) while liver biopsy remains the gold standard for diagnosis in clinical trials, further studies are needed to develop easy-to-use panels of serum and imaging-based biomarkers for noninvasive patient selection and treatment response; 2) given the complex pathophysiology of NASH and modest treatment response rates to individual drugs, it is highly likely that a combination treatment will also be required; and 3) the external validity of the RCT results should be confirmed, especially for real-world patients with NASH with more significant comorbidities. We believe that numerous drugs added to the pipeline of novel therapies could increase the chances of successful treatment of NASH and more completely reverse disease progression in affected patients in the future.</p></sec></body><back><ack><p>This study was supported by grant from the National Research Foundation of Korea funded by the Ministry of Science and ICT (RS-2022-00166674).</p></ack><fn-group><fn fn-type="participating-researchers"><p>
<bold>Authors&#8217; contribution</bold>
</p><p>Study concept and design: Jihyun An and Joo Hyun Sohn; Data analysis and interpretation: Jihyun An and Joo Hyun Sohn; Wrote the paper: Jihyun An and Joo Hyun Sohn; All authors have read and approved the final version of the manuscript.</p></fn><fn fn-type="COI-statement"><p>
<bold>Conflicts of Interest</bold>
</p><p>The authors have no conflicts to disclose.</p></fn></fn-group><glossary><title>Abbreviations</title><def-list><def-item><term>NAFLD</term><def><p>nonalcoholic fatty liver disease</p></def></def-item><def-item><term>NASH</term><def><p>nonalcoholic steatohepatitis</p></def></def-item><def-item><term>GLP-1</term><def><p>glucagon-like peptide 1</p></def></def-item><def-item><term>RCTs</term><def><p>randomized controlled trials</p></def></def-item><def-item><term>PPAR</term><def><p>peroxisome proliferator-activated receptor</p></def></def-item><def-item><term>SAF</term><def><p>steatosis</p></def></def-item><def-item><term>THR-&#946;</term><def><p>thyroid hormone receptor beta</p></def></def-item><def-item><term>MRI</term><def><p>magnetic resonance imaging</p></def></def-item><def-item><term>ASK1</term><def><p>apoptosis-signal regulating kinase 1</p></def></def-item><def-item><term>MAPK</term><def><p>mitogen-activated protein kinase</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="b1-cmh-2022-0437"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Younossi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tacke</surname><given-names>F</given-names></name><name name-style="western"><surname>Arrese</surname><given-names>M</given-names></name><name name-style="western"><surname>Chander Sharma</surname><given-names>B</given-names></name><name name-style="western"><surname>Mostafa</surname><given-names>I</given-names></name><etal/></person-group><article-title>Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis</article-title><source>Hepatology</source><year>2019</year><volume>69</volume><fpage>2672</fpage><lpage>2682</lpage><pub-id pub-id-type="pmid">30179269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.30251</pub-id></element-citation></ref><ref id="b2-cmh-2022-0437"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>SH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HW</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Cho</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SU</given-names></name><name name-style="western"><surname>Lee</surname><given-names>TH</given-names></name><etal/><collab>Korean Association for the Study of the Liver (KASL)</collab></person-group><article-title>KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease</article-title><source>Clin Mol Hepatol</source><year>2021</year><volume>27</volume><fpage>363</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">34154309</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3350/cmh.2021.0178</pub-id><pub-id pub-id-type="pmcid">PMC8273632</pub-id></element-citation></ref><ref id="b3-cmh-2022-0437"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dulai</surname><given-names>PS</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name><name name-style="western"><surname>Patel</surname><given-names>J</given-names></name><name name-style="western"><surname>Soni</surname><given-names>M</given-names></name><name name-style="western"><surname>Prokop</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Younossi</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis</article-title><source>Hepatology</source><year>2017</year><volume>65</volume><fpage>1557</fpage><lpage>1565</lpage><pub-id pub-id-type="pmid">28130788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.29085</pub-id><pub-id pub-id-type="pmcid">PMC5397356</pub-id></element-citation></ref><ref id="b4-cmh-2022-0437"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matteoni</surname><given-names>CA</given-names></name><name name-style="western"><surname>Younossi</surname><given-names>ZM</given-names></name><name name-style="western"><surname>Gramlich</surname><given-names>T</given-names></name><name name-style="western"><surname>Boparai</surname><given-names>N</given-names></name><name name-style="western"><surname>Liu</surname><given-names>YC</given-names></name><name name-style="western"><surname>McCullough</surname><given-names>AJ</given-names></name></person-group><article-title>Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity</article-title><source>Gastroenterology</source><year>1999</year><volume>116</volume><fpage>1413</fpage><lpage>1419</lpage><pub-id pub-id-type="pmid">10348825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0016-5085(99)70506-8</pub-id></element-citation></ref><ref id="b5-cmh-2022-0437"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noureddin</surname><given-names>M</given-names></name><name name-style="western"><surname>Vipani</surname><given-names>A</given-names></name><name name-style="western"><surname>Bresee</surname><given-names>C</given-names></name><name name-style="western"><surname>Todo</surname><given-names>T</given-names></name><name name-style="western"><surname>Kim</surname><given-names>IK</given-names></name><name name-style="western"><surname>Alkhouri</surname><given-names>N</given-names></name><etal/></person-group><article-title>NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances</article-title><source>Am J Gastroenterol</source><year>2018</year><volume>113</volume><fpage>1649</fpage><lpage>1659</lpage><pub-id pub-id-type="pmid">29880964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41395-018-0088-6</pub-id><pub-id pub-id-type="pmcid">PMC9083888</pub-id></element-citation></ref><ref id="b6-cmh-2022-0437"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anstee</surname><given-names>QM</given-names></name><name name-style="western"><surname>Reeves</surname><given-names>HL</given-names></name><name name-style="western"><surname>Kotsiliti</surname><given-names>E</given-names></name><name name-style="western"><surname>Govaere</surname><given-names>O</given-names></name><name name-style="western"><surname>Heikenwalder</surname><given-names>M</given-names></name></person-group><article-title>From NASH to HCC: current concepts and future challenges</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2019</year><volume>16</volume><fpage>411</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">31028350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41575-019-0145-7</pub-id></element-citation></ref><ref id="b7-cmh-2022-0437"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chalasani</surname><given-names>N</given-names></name><name name-style="western"><surname>Younossi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lavine</surname><given-names>JE</given-names></name><name name-style="western"><surname>Charlton</surname><given-names>M</given-names></name><name name-style="western"><surname>Cusi</surname><given-names>K</given-names></name><name name-style="western"><surname>Rinella</surname><given-names>M</given-names></name><etal/></person-group><article-title>The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases</article-title><source>Hepatology</source><year>2018</year><volume>67</volume><fpage>328</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">28714183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.29367</pub-id></element-citation></ref><ref id="b8-cmh-2022-0437"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vilar-Gomez</surname><given-names>E</given-names></name><name name-style="western"><surname>Martinez-Perez</surname><given-names>Y</given-names></name><name name-style="western"><surname>Calzadilla-Bertot</surname><given-names>L</given-names></name><name name-style="western"><surname>TorresGonzalez</surname><given-names>A</given-names></name><name name-style="western"><surname>Gra-Oramas</surname><given-names>B</given-names></name><name name-style="western"><surname>Gonzalez-Fabian</surname><given-names>L</given-names></name><etal/></person-group><article-title>Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis</article-title><source>Gastroenterology</source><year>2015</year><volume>149</volume><fpage>367</fpage><lpage>378.e5</lpage><comment>quiz e14-5</comment><pub-id pub-id-type="pmid">25865049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2015.04.005</pub-id></element-citation></ref><ref id="b9-cmh-2022-0437"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hydes</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Ravi</surname><given-names>S</given-names></name><name name-style="western"><surname>Loomba</surname><given-names>R</given-names></name><name name-style="western"><surname>E Gray</surname><given-names>M</given-names></name></person-group><article-title>Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH</article-title><source>Clin Mol Hepatol</source><year>2020</year><volume>26</volume><fpage>383</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">32674529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3350/cmh.2020.0067</pub-id><pub-id pub-id-type="pmcid">PMC7641567</pub-id></element-citation></ref><ref id="b10-cmh-2022-0437"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>VW</given-names></name><name name-style="western"><surname>Wong</surname><given-names>GL</given-names></name><name name-style="western"><surname>Chan</surname><given-names>RS</given-names></name><name name-style="western"><surname>Shu</surname><given-names>SS</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>BH</given-names></name><name name-style="western"><surname>Li</surname><given-names>LS</given-names></name><etal/></person-group><article-title>Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease</article-title><source>J Hepatol</source><year>2018</year><volume>69</volume><fpage>1349</fpage><lpage>1356</lpage><pub-id pub-id-type="pmid">30142427</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2018.08.011</pub-id></element-citation></ref><ref id="b11-cmh-2022-0437"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franz</surname><given-names>MJ</given-names></name><name name-style="western"><surname>VanWormer</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Crain</surname><given-names>AL</given-names></name><name name-style="western"><surname>Boucher</surname><given-names>JL</given-names></name><name name-style="western"><surname>Histon</surname><given-names>T</given-names></name><name name-style="western"><surname>Caplan</surname><given-names>W</given-names></name><etal/></person-group><article-title>Weight-loss outcomes: a systematic review and metaanalysis of weight-loss clinical trials with a minimum 1-year follow-up</article-title><source>J Am Diet Assoc</source><year>2007</year><volume>107</volume><fpage>1755</fpage><lpage>1767</lpage><pub-id pub-id-type="pmid">17904936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jada.2007.07.017</pub-id></element-citation></ref><ref id="b12-cmh-2022-0437"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanyal</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Chalasani</surname><given-names>N</given-names></name><name name-style="western"><surname>Kowdley</surname><given-names>KV</given-names></name><name name-style="western"><surname>McCullough</surname><given-names>A</given-names></name><name name-style="western"><surname>Diehl</surname><given-names>AM</given-names></name><name name-style="western"><surname>Bass</surname><given-names>NM</given-names></name><etal/><collab>NASH CRN</collab></person-group><article-title>Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis</article-title><source>N Engl J Med</source><year>2010</year><volume>362</volume><fpage>1675</fpage><lpage>1685</lpage><pub-id pub-id-type="pmid">20427778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa0907929</pub-id><pub-id pub-id-type="pmcid">PMC2928471</pub-id></element-citation></ref><ref id="b13-cmh-2022-0437"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel Chavez</surname><given-names>C</given-names></name><name name-style="western"><surname>Cusi</surname><given-names>K</given-names></name><name name-style="western"><surname>Kadiyala</surname><given-names>S</given-names></name></person-group><article-title>The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD</article-title><source>J Clin Endocrinol Metab</source><year>2022</year><volume>107</volume><fpage>29</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">34406410</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/clinem/dgab578</pub-id><pub-id pub-id-type="pmcid">PMC8684453</pub-id></element-citation></ref><ref id="b14-cmh-2022-0437"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arroyave-Ospina</surname><given-names>JC</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Geng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Moshage</surname><given-names>H</given-names></name></person-group><article-title>Role of oxidative stress in the pathogenesis of non-alcoholic fatty liver disease: implications for prevention and therapy</article-title><source>Antioxidants (Basel)</source><year>2021</year><volume>10</volume><fpage>174</fpage><pub-id pub-id-type="pmid">33530432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antiox10020174</pub-id><pub-id pub-id-type="pmcid">PMC7911109</pub-id></element-citation></ref><ref id="b15-cmh-2022-0437"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Q</given-names></name></person-group><article-title>Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy</article-title><source>Free Radic Biol Med</source><year>2014</year><volume>72</volume><fpage>76</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">24704972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.freeradbiomed.2014.03.035</pub-id><pub-id pub-id-type="pmcid">PMC4120831</pub-id></element-citation></ref><ref id="b16-cmh-2022-0437"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bril</surname><given-names>F</given-names></name><name name-style="western"><surname>Biernacki</surname><given-names>DM</given-names></name><name name-style="western"><surname>Kalavalapalli</surname><given-names>S</given-names></name><name name-style="western"><surname>Lomonaco</surname><given-names>R</given-names></name><name name-style="western"><surname>Subbarayan</surname><given-names>SK</given-names></name><name name-style="western"><surname>Lai</surname><given-names>J</given-names></name><etal/></person-group><article-title>Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial</article-title><source>Diabetes Care</source><year>2019</year><volume>42</volume><fpage>1481</fpage><lpage>1488</lpage><pub-id pub-id-type="pmid">31332029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc19-0167</pub-id></element-citation></ref><ref id="b17-cmh-2022-0437"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cusi</surname><given-names>K</given-names></name><name name-style="western"><surname>Isaacs</surname><given-names>S</given-names></name><name name-style="western"><surname>Barb</surname><given-names>D</given-names></name><name name-style="western"><surname>Basu</surname><given-names>R</given-names></name><name name-style="western"><surname>Caprio</surname><given-names>S</given-names></name><name name-style="western"><surname>Garvey</surname><given-names>WT</given-names></name><etal/></person-group><article-title>American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD)</article-title><source>Endocr Pract</source><year>2022</year><volume>28</volume><fpage>528</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">35569886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eprac.2022.03.010</pub-id></element-citation></ref><ref id="b18-cmh-2022-0437"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klein</surname><given-names>EA</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>IM</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Tangen</surname><given-names>CM</given-names></name><name name-style="western"><surname>Crowley</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Lucia</surname><given-names>MS</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)</article-title><source>JAMA</source><year>2011</year><volume>306</volume><fpage>1549</fpage><lpage>1556</lpage><pub-id pub-id-type="pmid">21990298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2011.1437</pub-id><pub-id pub-id-type="pmcid">PMC4169010</pub-id></element-citation></ref><ref id="b19-cmh-2022-0437"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belfort</surname><given-names>R</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>SA</given-names></name><name name-style="western"><surname>Brown</surname><given-names>K</given-names></name><name name-style="western"><surname>Darland</surname><given-names>C</given-names></name><name name-style="western"><surname>Finch</surname><given-names>J</given-names></name><name name-style="western"><surname>Hardies</surname><given-names>J</given-names></name><etal/></person-group><article-title>A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis</article-title><source>N Engl J Med</source><year>2006</year><volume>355</volume><fpage>2297</fpage><lpage>2307</lpage><pub-id pub-id-type="pmid">17135584</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa060326</pub-id></element-citation></ref><ref id="b20-cmh-2022-0437"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aithal</surname><given-names>GP</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>JA</given-names></name><name name-style="western"><surname>Kaye</surname><given-names>PV</given-names></name><name name-style="western"><surname>Lawson</surname><given-names>A</given-names></name><name name-style="western"><surname>Ryder</surname><given-names>SD</given-names></name><name name-style="western"><surname>Spendlove</surname><given-names>I</given-names></name><etal/></person-group><article-title>Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis</article-title><source>Gastroenterology</source><year>2008</year><volume>135</volume><fpage>1176</fpage><lpage>1184</lpage><pub-id pub-id-type="pmid">18718471</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2008.06.047</pub-id></element-citation></ref><ref id="b21-cmh-2022-0437"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cusi</surname><given-names>K</given-names></name><name name-style="western"><surname>Orsak</surname><given-names>B</given-names></name><name name-style="western"><surname>Bril</surname><given-names>F</given-names></name><name name-style="western"><surname>Lomonaco</surname><given-names>R</given-names></name><name name-style="western"><surname>Hecht</surname><given-names>J</given-names></name><name name-style="western"><surname>Ortiz-Lopez</surname><given-names>C</given-names></name><etal/></person-group><article-title>Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial</article-title><source>Ann Intern Med</source><year>2016</year><volume>165</volume><fpage>305</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">27322798</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M15-1774</pub-id></element-citation></ref><ref id="b22-cmh-2022-0437"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Musso</surname><given-names>G</given-names></name><name name-style="western"><surname>Cassader</surname><given-names>M</given-names></name><name name-style="western"><surname>Paschetta</surname><given-names>E</given-names></name><name name-style="western"><surname>Gambino</surname><given-names>R</given-names></name></person-group><article-title>Thiazolidinediones and Advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis</article-title><source>JAMA Intern Med</source><year>2017</year><volume>177</volume><fpage>633</fpage><lpage>640</lpage><comment>Erratum in: JAMA Intern Med 2017;177:747</comment><pub-id pub-id-type="pmid">28241279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamainternmed.2016.9607</pub-id><pub-id pub-id-type="pmcid">PMC5470366</pub-id></element-citation></ref><ref id="b23-cmh-2022-0437"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>KS</given-names></name><name name-style="western"><surname>Lee</surname><given-names>BW</given-names></name></person-group><article-title>Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease</article-title><source>Clin Mol Hepatol</source><year>2020</year><volume>26</volume><fpage>430</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">32791578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3350/cmh.2020.0137</pub-id><pub-id pub-id-type="pmcid">PMC7641556</pub-id></element-citation></ref><ref id="b24-cmh-2022-0437"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newsome</surname><given-names>PN</given-names></name><name name-style="western"><surname>Buchholtz</surname><given-names>K</given-names></name><name name-style="western"><surname>Cusi</surname><given-names>K</given-names></name><name name-style="western"><surname>Linder</surname><given-names>M</given-names></name><name name-style="western"><surname>Okanoue</surname><given-names>T</given-names></name><name name-style="western"><surname>Ratziu</surname><given-names>V</given-names></name><etal/><collab>NN9931-4296 Investigators</collab></person-group><article-title>A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis</article-title><source>N Engl J Med</source><year>2021</year><volume>384</volume><fpage>1113</fpage><lpage>1124</lpage><pub-id pub-id-type="pmid">33185364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2028395</pub-id></element-citation></ref><ref id="b25-cmh-2022-0437"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Day</surname><given-names>JW</given-names></name><name name-style="western"><surname>Ottaway</surname><given-names>N</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>JT</given-names></name><name name-style="western"><surname>Gelfanov</surname><given-names>V</given-names></name><name name-style="western"><surname>Smiley</surname><given-names>D</given-names></name><name name-style="western"><surname>Gidda</surname><given-names>J</given-names></name><etal/></person-group><article-title>A new glucagon and GLP-1 co-agonist eliminates obesity in rodents</article-title><source>Nat Chem Biol</source><year>2009</year><volume>5</volume><fpage>749</fpage><lpage>757</lpage><pub-id pub-id-type="pmid">19597507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nchembio.209</pub-id></element-citation></ref><ref id="b26-cmh-2022-0437"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robertson</surname><given-names>D</given-names></name><name name-style="western"><surname>Challis</surname><given-names>B</given-names></name><name name-style="western"><surname>Daniels</surname><given-names>JS</given-names></name><name name-style="western"><surname>Sarv</surname><given-names>J</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>J</given-names></name><name name-style="western"><surname>Schumi</surname><given-names>J</given-names></name><etal/></person-group><article-title>PROXYMO demonstrates safety and efficacy of cotadutide, a novel incretin co-agonist in biopsy-proven non-cirrhotic NASH with fibrosis. Oral abstract</article-title><source>Hepatology</source><year>2021</year><volume>74</volume><fpage>1383A</fpage></element-citation></ref><ref id="b27-cmh-2022-0437"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Modica</surname><given-names>S</given-names></name><name name-style="western"><surname>Gadaleta</surname><given-names>RM</given-names></name><name name-style="western"><surname>Moschetta</surname><given-names>A</given-names></name></person-group><article-title>Deciphering the nuclear bile acid receptor FXR paradigm</article-title><source>Nucl Recept Signal</source><year>2010</year><volume>8</volume><fpage>e005</fpage><pub-id pub-id-type="pmid">21383957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1621/nrs.08005</pub-id><pub-id pub-id-type="pmcid">PMC3049226</pub-id></element-citation></ref><ref id="b28-cmh-2022-0437"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Claudel</surname><given-names>T</given-names></name><name name-style="western"><surname>Staels</surname><given-names>B</given-names></name><name name-style="western"><surname>Kuipers</surname><given-names>F</given-names></name></person-group><article-title>The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2005</year><volume>25</volume><fpage>2020</fpage><lpage>2030</lpage><pub-id pub-id-type="pmid">16037564</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.ATV.0000178994.21828.a7</pub-id></element-citation></ref><ref id="b29-cmh-2022-0437"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiorucci</surname><given-names>S</given-names></name><name name-style="western"><surname>Antonelli</surname><given-names>E</given-names></name><name name-style="western"><surname>Rizzo</surname><given-names>G</given-names></name><name name-style="western"><surname>Renga</surname><given-names>B</given-names></name><name name-style="western"><surname>Mencarelli</surname><given-names>A</given-names></name><name name-style="western"><surname>Riccardi</surname><given-names>L</given-names></name><etal/></person-group><article-title>The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis</article-title><source>Gastroenterology</source><year>2004</year><volume>127</volume><fpage>1497</fpage><lpage>1512</lpage><pub-id pub-id-type="pmid">15521018</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2004.08.001</pub-id></element-citation></ref><ref id="b30-cmh-2022-0437"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>YD</given-names></name><name name-style="western"><surname>Chen</surname><given-names>WD</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D</given-names></name><name name-style="western"><surname>Forman</surname><given-names>BM</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W</given-names></name></person-group><article-title>Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response</article-title><source>Hepatology</source><year>2008</year><volume>48</volume><fpage>1632</fpage><lpage>1643</lpage><pub-id pub-id-type="pmid">18972444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.22519</pub-id><pub-id pub-id-type="pmcid">PMC3056574</pub-id></element-citation></ref><ref id="b31-cmh-2022-0437"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Younossi</surname><given-names>ZM</given-names></name><name name-style="western"><surname>Ratziu</surname><given-names>V</given-names></name><name name-style="western"><surname>Loomba</surname><given-names>R</given-names></name><name name-style="western"><surname>Rinella</surname><given-names>M</given-names></name><name name-style="western"><surname>Anstee</surname><given-names>QM</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>Z</given-names></name><etal/><collab>REGENERATE Study Investigators</collab></person-group><article-title>Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial</article-title><source>Lancet</source><year>2020</year><volume>394</volume><fpage>2184</fpage><lpage>2196</lpage><comment>Erratum in: Lancet 2020;396:312. Erratum in: Lancet 2021;397:2336</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(19)33041-7</pub-id><pub-id pub-id-type="pmid">31813633</pub-id></element-citation></ref><ref id="b32-cmh-2022-0437"><label>32</label><element-citation publication-type="unknown"><comment>Intercept Pharmaceuticals. Intercept pharmaceuticals announces REVERSE phase 3 study of obeticholic acid (OCA) in compensated cirrhosis due to NASH did not meet its primary endpoint. Intercept web site, &lt;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ir.interceptpharma.com/newsreleases/news-release-details/intercept-pharmaceuticalsannounces-reverse-phase-3-study" ext-link-type="uri">https://ir.interceptpharma.com/newsreleases/news-release-details/intercept-pharmaceuticalsannounces-reverse-phase-3-study</ext-link>&gt;. Press release; 30 Sep 2006. Accessed 1 Dec 2022</comment></element-citation></ref><ref id="b33-cmh-2022-0437"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Francque</surname><given-names>S</given-names></name><name name-style="western"><surname>Szabo</surname><given-names>G</given-names></name><name name-style="western"><surname>Abdelmalek</surname><given-names>MF</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>CD</given-names></name><name name-style="western"><surname>Cusi</surname><given-names>K</given-names></name><name name-style="western"><surname>Dufour</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2021</year><volume>18</volume><fpage>24</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">33093663</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41575-020-00366-5</pub-id></element-citation></ref><ref id="b34-cmh-2022-0437"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wettstein</surname><given-names>G</given-names></name><name name-style="western"><surname>Luccarini</surname><given-names>JM</given-names></name><name name-style="western"><surname>Poekes</surname><given-names>L</given-names></name><name name-style="western"><surname>Faye</surname><given-names>P</given-names></name><name name-style="western"><surname>Kupkowski</surname><given-names>F</given-names></name><name name-style="western"><surname>Adarbes</surname><given-names>V</given-names></name><etal/></person-group><article-title>The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis</article-title><source>Hepatol Commun</source><year>2017</year><volume>1</volume><fpage>524</fpage><lpage>537</lpage><pub-id pub-id-type="pmid">29404476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep4.1057</pub-id><pub-id pub-id-type="pmcid">PMC5678909</pub-id></element-citation></ref><ref id="b35-cmh-2022-0437"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lefere</surname><given-names>S</given-names></name><name name-style="western"><surname>Puengel</surname><given-names>T</given-names></name><name name-style="western"><surname>Hundertmark</surname><given-names>J</given-names></name><name name-style="western"><surname>Penners</surname><given-names>C</given-names></name><name name-style="western"><surname>Frank</surname><given-names>AK</given-names></name><name name-style="western"><surname>Guillot</surname><given-names>A</given-names></name><etal/></person-group><article-title>Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages</article-title><source>J Hepatol</source><year>2020</year><volume>73</volume><fpage>757</fpage><lpage>770</lpage><pub-id pub-id-type="pmid">32360434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2020.04.025</pub-id></element-citation></ref><ref id="b36-cmh-2022-0437"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Francque</surname><given-names>SM</given-names></name><name name-style="western"><surname>Bedossa</surname><given-names>P</given-names></name><name name-style="western"><surname>Ratziu</surname><given-names>V</given-names></name><name name-style="western"><surname>Anstee</surname><given-names>QM</given-names></name><name name-style="western"><surname>Bugianesi</surname><given-names>E</given-names></name><name name-style="western"><surname>Sanyal</surname><given-names>AJ</given-names></name><etal/><collab>NATIVE Study Group</collab></person-group><article-title>A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH</article-title><source>N Engl J Med</source><year>2021</year><volume>385</volume><fpage>1547</fpage><lpage>1558</lpage><pub-id pub-id-type="pmid">34670042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2036205</pub-id></element-citation></ref><ref id="b37-cmh-2022-0437"><label>37</label><element-citation publication-type="webpage"><comment>National Library of Medicine. Phase 3 study to evaluate the efficacy and safety of elafibranor versus placebo in patients with nonalcoholic steatohepatitis (NASH) (RESOLVE-IT). National Library of Medicine web site, &lt;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02704403" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT02704403</ext-link>&gt;. Accessed 1 Dec 2022</comment></element-citation></ref><ref id="b38-cmh-2022-0437"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reinehr</surname><given-names>T</given-names></name></person-group><article-title>Obesity and thyroid function</article-title><source>Mol Cell Endocrinol</source><year>2010</year><volume>316</volume><fpage>165</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">19540303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mce.2009.06.005</pub-id></element-citation></ref><ref id="b39-cmh-2022-0437"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinha</surname><given-names>RA</given-names></name><name name-style="western"><surname>Bruinstroop</surname><given-names>E</given-names></name><name name-style="western"><surname>Singh</surname><given-names>BK</given-names></name><name name-style="western"><surname>Yen</surname><given-names>PM</given-names></name></person-group><article-title>Nonalcoholic fatty liver disease and hypercholesterolemia: roles of thyroid hormones, metabolites, and agonists</article-title><source>Thyroid</source><year>2019</year><volume>29</volume><fpage>1173</fpage><lpage>1191</lpage><pub-id pub-id-type="pmid">31389309</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/thy.2018.0664</pub-id><pub-id pub-id-type="pmcid">PMC6850905</pub-id></element-citation></ref><ref id="b40-cmh-2022-0437"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrison</surname><given-names>SA</given-names></name><name name-style="western"><surname>Bashir</surname><given-names>MR</given-names></name><name name-style="western"><surname>Guy</surname><given-names>CD</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>R</given-names></name><name name-style="western"><surname>Moylan</surname><given-names>CA</given-names></name><name name-style="western"><surname>Frias</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial</article-title><source>Lancet</source><year>2019</year><volume>394</volume><fpage>2012</fpage><lpage>2024</lpage><pub-id pub-id-type="pmid">31727409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(19)32517-6</pub-id></element-citation></ref><ref id="b41-cmh-2022-0437"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrison</surname><given-names>S</given-names></name><name name-style="western"><surname>Taub</surname><given-names>R</given-names></name><name name-style="western"><surname>Neff</surname><given-names>G</given-names></name><name name-style="western"><surname>Moussa</surname><given-names>S</given-names></name><name name-style="western"><surname>Alkhouri</surname><given-names>N</given-names></name><name name-style="western"><surname>Bashir</surname><given-names>MJJoH</given-names></name></person-group><article-title>Primary data analyses of MAESTRO-NAFLD-1 a 52 week doubleblind placebo-controlled phase 3 clinical trial of resmetirom in patients with NAFLD</article-title><source>J Hepatol</source><year>2022</year><volume>77</volume><fpage>S14</fpage></element-citation></ref><ref id="b42-cmh-2022-0437"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ichijo</surname><given-names>H</given-names></name><name name-style="western"><surname>Nishida</surname><given-names>E</given-names></name><name name-style="western"><surname>Irie</surname><given-names>K</given-names></name><name name-style="western"><surname>ten Dijke</surname><given-names>P</given-names></name><name name-style="western"><surname>Saitoh</surname><given-names>M</given-names></name><name name-style="western"><surname>Moriguchi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways</article-title><source>Science</source><year>1997</year><volume>275</volume><fpage>90</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">8974401</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.275.5296.90</pub-id></element-citation></ref><ref id="b43-cmh-2022-0437"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Odagiri</surname><given-names>N</given-names></name><name name-style="western"><surname>Matsubara</surname><given-names>T</given-names></name><name name-style="western"><surname>Sato-Matsubara</surname><given-names>M</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>H</given-names></name><name name-style="western"><surname>Enomoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Kawada</surname><given-names>N</given-names></name></person-group><article-title>Anti-fibrotic treatments for chronic liver diseases: the present and the future</article-title><source>Clin Mol Hepatol</source><year>2021</year><volume>27</volume><fpage>413</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">33317250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3350/cmh.2020.0187</pub-id><pub-id pub-id-type="pmcid">PMC8273638</pub-id></element-citation></ref><ref id="b44-cmh-2022-0437"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loomba</surname><given-names>R</given-names></name><name name-style="western"><surname>Lawitz</surname><given-names>E</given-names></name><name name-style="western"><surname>Mantry</surname><given-names>PS</given-names></name><name name-style="western"><surname>Jayakumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Caldwell</surname><given-names>SH</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>H</given-names></name><etal/><collab>GS-US-384-1497 Investigators</collab></person-group><article-title>The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial</article-title><source>Hepatology</source><year>2018</year><volume>67</volume><fpage>549</fpage><lpage>559</lpage><comment>Erratum in: Hepatology 2018;67:2063</comment><pub-id pub-id-type="pmid">28892558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.29514</pub-id><pub-id pub-id-type="pmcid">PMC5814892</pub-id></element-citation></ref><ref id="b45-cmh-2022-0437"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrison</surname><given-names>SA</given-names></name><name name-style="western"><surname>Wong</surname><given-names>VW</given-names></name><name name-style="western"><surname>Okanoue</surname><given-names>T</given-names></name><name name-style="western"><surname>Bzowej</surname><given-names>N</given-names></name><name name-style="western"><surname>Vuppalanchi</surname><given-names>R</given-names></name><name name-style="western"><surname>Younes</surname><given-names>Z</given-names></name><etal/><collab>STELLAR-3 and STELLAR-4 Investigators</collab></person-group><article-title>Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials</article-title><source>J Hepatol</source><year>2020</year><volume>73</volume><fpage>26</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">32147362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2020.02.027</pub-id></element-citation></ref><ref id="b46-cmh-2022-0437"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loomba</surname><given-names>R</given-names></name><name name-style="western"><surname>Noureddin</surname><given-names>M</given-names></name><name name-style="western"><surname>Kowdley</surname><given-names>KV</given-names></name><name name-style="western"><surname>Kohli</surname><given-names>A</given-names></name><name name-style="western"><surname>Sheikh</surname><given-names>A</given-names></name><name name-style="western"><surname>Neff</surname><given-names>G</given-names></name><etal/><collab>ATLAS Investigators</collab></person-group><article-title>Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH</article-title><source>Hepatology</source><year>2021</year><volume>73</volume><fpage>625</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">33169409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.31622</pub-id></element-citation></ref><ref id="b47-cmh-2022-0437"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ajmera</surname><given-names>VH</given-names></name><name name-style="western"><surname>Cachay</surname><given-names>E</given-names></name><name name-style="western"><surname>Ramers</surname><given-names>C</given-names></name><name name-style="western"><surname>Vodkin</surname><given-names>I</given-names></name><name name-style="western"><surname>Bassirian</surname><given-names>S</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name><etal/></person-group><article-title>MRI assessment of treatment response in HIV-associated NAFLD: a randomized trial of a Stearoyl-Coenzyme-A-Desaturase-1 inhibitor (ARRIVE trial)</article-title><source>Hepatology</source><year>2019</year><volume>70</volume><fpage>1531</fpage><lpage>1545</lpage><pub-id pub-id-type="pmid">31013363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.30674</pub-id><pub-id pub-id-type="pmcid">PMC7164416</pub-id></element-citation></ref><ref id="b48-cmh-2022-0437"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedman</surname><given-names>SL</given-names></name><name name-style="western"><surname>Ratziu</surname><given-names>V</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>SA</given-names></name><name name-style="western"><surname>Abdelmalek</surname><given-names>MF</given-names></name><name name-style="western"><surname>Aithal</surname><given-names>GP</given-names></name><name name-style="western"><surname>Caballeria</surname><given-names>J</given-names></name><etal/></person-group><article-title>A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis</article-title><source>Hepatology</source><year>2018</year><volume>67</volume><fpage>1754</fpage><lpage>1767</lpage><pub-id pub-id-type="pmid">28833331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.29477</pub-id><pub-id pub-id-type="pmcid">PMC5947654</pub-id></element-citation></ref><ref id="b49-cmh-2022-0437"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Attia</surname><given-names>SL</given-names></name><name name-style="western"><surname>Softic</surname><given-names>S</given-names></name><name name-style="western"><surname>Mouzaki</surname><given-names>M</given-names></name></person-group><article-title>Evolving role for pharmacotherapy in NAFLD/NASH</article-title><source>Clin Transl Sci</source><year>2021</year><volume>14</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">32583961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cts.12839</pub-id><pub-id pub-id-type="pmcid">PMC7877845</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap position="float" id="t1-cmh-2022-0437" orientation="portrait"><label>Table 1.</label><caption><p>Summary of current NASH medications recommended by international guidelines</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Drugs</th><th align="center" valign="middle" rowspan="1" colspan="1">Mechanism</th><th align="center" valign="middle" rowspan="1" colspan="1">Population</th><th align="center" valign="middle" rowspan="1" colspan="1">Guidelines (level of recommendation)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="4" colspan="1">Vitamin E</td><td valign="top" align="left" rowspan="4" colspan="1">Anti-oxidant</td><td valign="top" align="left" rowspan="4" colspan="1">Non-diabetic patients with biopsy-proven NASH</td><td valign="top" align="left" rowspan="1" colspan="1">AASLD 2018<sup><xref rid="tfn1-cmh-2022-0437" ref-type="table-fn">*</xref></sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EASL 2016 (B2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">KASL 2021 (B1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AACE 2022 (Grade B, high strength of evidence)</td></tr><tr><td valign="top" align="left" rowspan="4" colspan="1">Pioglitazone</td><td valign="top" align="left" rowspan="4" colspan="1">PPAR-&#947; agonist</td><td valign="top" align="left" rowspan="4" colspan="1">Diabetic patients with biopsy- proven NASH</td><td valign="top" align="left" rowspan="1" colspan="1">AASLD 2018<sup><xref rid="tfn1-cmh-2022-0437" ref-type="table-fn">*</xref></sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EASL 2016 (B2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">KASL 2021 (B1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AACE 2022 (Grade A, high strength of evidence)</td></tr></tbody></table><table-wrap-foot><fn><p>NASH, nonalcoholic steatohepatitis; PPAR, peroxisome proliferator-activated receptor; AASLD, American Association for the Study of Liver Diseases; EASL, European Association for the Study of the Liver; KASL, Korean Association for the Study of the Liver; AACE, American Association of Clinical Endocrinology.</p></fn><fn id="tfn1-cmh-2022-0437"><label>*</label><p>The level and length of recommendations were not presented in the AASLD guidance 2018.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t2-cmh-2022-0437" orientation="portrait"><label>Table 2.</label><caption><p>Current status of emerging drugs from phase 3 clinical trials of nonalcoholic steatohepatitis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Drug</th><th align="center" valign="middle" rowspan="1" colspan="1">Target</th><th align="center" valign="middle" rowspan="1" colspan="1">Population</th><th align="center" valign="middle" rowspan="1" colspan="1">Study name</th><th align="center" valign="middle" rowspan="1" colspan="1">Status</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Obeticholic acid</td><td valign="top" align="left" rowspan="1" colspan="1">Farnesoid X receptor agonist</td><td valign="top" align="left" rowspan="1" colspan="1">NASH with F2-F3 fibrosis</td><td valign="top" align="left" rowspan="1" colspan="1">REGENERATE</td><td valign="top" align="left" rowspan="1" colspan="1">Ongoing</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lanifibranor</td><td valign="top" align="left" rowspan="1" colspan="1">Pan-PPAR agonist</td><td valign="top" align="left" rowspan="1" colspan="1">NASH with F2-F3 fibrosis</td><td valign="top" align="left" rowspan="1" colspan="1">NATiV3</td><td valign="top" align="left" rowspan="1" colspan="1">Ongoing</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Resmetirom</td><td valign="top" align="left" rowspan="1" colspan="1">Thyroid hormone receptor-beta agonist</td><td valign="top" align="left" rowspan="1" colspan="1">NASH with F1-F3 fibrosis</td><td valign="top" align="left" rowspan="1" colspan="1">MAESTRO-NASH</td><td valign="top" align="left" rowspan="1" colspan="1">Ongoing</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Semaglutide</td><td valign="top" align="left" rowspan="1" colspan="1">Glucagon-like peptide-1 (GLP-1) agonist</td><td valign="top" align="left" rowspan="1" colspan="1">NASH with F2-F3 fibrosis</td><td valign="top" align="left" rowspan="1" colspan="1">ESSENCE</td><td valign="top" align="left" rowspan="1" colspan="1">Ongoing</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cotadutide</td><td valign="top" align="left" rowspan="1" colspan="1">dual GLP-1 and glucagon receptor agonist</td><td valign="top" align="left" rowspan="1" colspan="1">NASH with F2-F3 fibrosis</td><td valign="top" align="left" rowspan="1" colspan="1">PROXYMO-ADV</td><td valign="top" align="left" rowspan="1" colspan="1">Ongoing</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Obeticholic acid</td><td valign="top" align="left" rowspan="1" colspan="1">Farnesoid X receptor agonist</td><td valign="top" align="left" rowspan="1" colspan="1">NASH with compensated LC</td><td valign="top" align="left" rowspan="1" colspan="1">REVERSE</td><td valign="top" align="left" rowspan="1" colspan="1">Halted</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Elafibranor</td><td valign="top" align="left" rowspan="1" colspan="1">PPAR-alpha and -delta agonist</td><td valign="top" align="left" rowspan="1" colspan="1">NASH with F1-F3 fibrosis</td><td valign="top" align="left" rowspan="1" colspan="1">RESOLVE-IT</td><td valign="top" align="left" rowspan="1" colspan="1">Halted</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Selonsertib</td><td valign="top" align="left" rowspan="1" colspan="1">Apoptosis signal-regulating kinase inhibitor</td><td valign="top" align="left" rowspan="1" colspan="1">NASH with F3 fibrosis</td><td valign="top" align="left" rowspan="1" colspan="1">STELLAR-3</td><td valign="top" align="left" rowspan="1" colspan="1">Halted</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Selonsertib</td><td valign="top" align="left" rowspan="1" colspan="1">Apoptosis signal-regulating kinase inhibitor</td><td valign="top" align="left" rowspan="1" colspan="1">NASH with compensated LC</td><td valign="top" align="left" rowspan="1" colspan="1">STELLAR-4</td><td valign="top" align="left" rowspan="1" colspan="1">Halted</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cenicriviroc</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibitor of CC chemokine receptors 2 and 5</td><td valign="top" align="left" rowspan="1" colspan="1">NASH with F2-F3 fibrosis</td><td valign="top" align="left" rowspan="1" colspan="1">AURORA</td><td valign="top" align="left" rowspan="1" colspan="1">Halted</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Aramchol</td><td valign="top" align="left" rowspan="1" colspan="1">Fatty acid bile acid conjugate</td><td valign="top" align="left" rowspan="1" colspan="1">NASH with F1-F3 fibrosis</td><td valign="top" align="left" rowspan="1" colspan="1">ARMOR</td><td valign="top" align="left" rowspan="1" colspan="1">Suspended<sup><xref rid="tfn2-cmh-2022-0437" ref-type="table-fn">*</xref></sup></td></tr></tbody></table><table-wrap-foot><fn><p>PPAR, peroxisome proliferator-activated receptor; NASH, nonalcoholic steatohepatitis; LC, liver cirrhosis.</p></fn><fn id="tfn2-cmh-2022-0437"><label>*</label><p>Starting the double-blind part of phase 3 trial is delayed due to the formulation of Aramchol Meglumine.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>